PharmAust Limited (ECQ.F)
Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
As of 08:18AM CEST. Market open.
| Previous close | 0.1370 |
| Open | 0.1410 |
| Bid | 0.1260 x 4500000 |
| Ask | 0.1430 x 3500000 |
| Day's range | 0.1410 - 0.1410 |
| 52-week range | 0.0310 - 0.2480 |
| Volume | |
| Avg. volume | 965 |
| Market cap | 43.61M |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswirePharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS
PharmAust Limited (ASX: PAA & PAAOA) ("PharmAust" or "the Company"), a clinical-stage biotechnology company, is pleased to announce that it has met its primary safety and tolerability endpoints with monepantel (MPL) and, importantly, demonstrated a positive signal of potential efficacy. Rates of disease progression in patients with Motor Neurone Disease (MND) / Amyotrophic Lateral Sclerosis (ALS) measured by changes in ALSFRS-R may be slowed by 58% for Cohort 2, when compared to an external cont
Simply Wall St.PharmAust (ASX:PAA) delivers shareholders incredible 42% CAGR over 5 years, surging 11% in the last week alone
We think all investors should try to buy and hold high quality multi-year winners. And we've seen some truly amazing...
- Simply Wall St.
PharmAust Full Year 2023 Earnings: AU$0.019 loss per share (vs AU$0.005 loss in FY 2022)
PharmAust ( ASX:PAA ) Full Year 2023 Results Key Financial Results Revenue: AU$3.90m (down 14% from FY 2022). Net loss...
© 2024 Yahoo. All rights reserved.